36938-75-7

Usage

Uses

Used in Medicinal Chemistry:
ALPHA-(4-CHLOROPHENYL)-4-PIPERIDINEMETHANOL is used as an intermediate in the synthesis of pharmaceutical drugs for its role in creating opioid receptor agonists and antagonists. Its unique structure allows it to be a key building block in the development of these medications, which are crucial for managing pain and addiction treatment.
Used in Research and Development:
In the scientific community, ALPHA-(4-CHLOROPHENYL)-4-PIPERIDINEMETHANOL serves as a valuable component in the synthesis of various biologically active compounds. Its presence in research and development efforts contributes to the advancement of new drug discoveries and the enhancement of existing pharmaceutical agents, broadening the scope of treatment options for various medical conditions.

InChI:InChI=1/C12H16ClNO/c13-11-3-1-9(2-4-11)12(15)10-5-7-14-8-6-10/h1-4,10,12,14-15H,5-8H2

Upstream product

• 36938-77-9 (pyridin-4-yl)-(4-chlorophenyl)methanol 
• 14548-48-2 4-(4-chlorobenzoyl)pyridine 
• 53220-41-0 4-(4-chlorobenzoyl)piperidine 

Downstream Products

• 38077-13-3 4-(p-Chloro-α-hydroxybenzyl)-1-[3-(p-fluorobenzoyl)propyl]piperidine 

Relevant academic research and scientific papers

Highly enantioselective hydrogenation and transfer hydrogenation of cycloalkyl and heterocyclic ketones catalysed by an iridium complex of a tridentate phosphine-diamine ligand

Ir complexes of chiral phosphine-diamine ligands catalyse the hydrogenation and transfer hydrogenation of aryl-piperidin-4-yl methanones, and ketones bearing both an aryl group and secondary alkyl substituent with up to 98% e.e., and with substrate to catalyst ratios of up to 4000.

Design, Synthesis, and Evaluation of Metabolism-Based Analogues of Haloperidol Incapable of Forming MPP+-like Species

The long-term, irreversible, Parkinsonism-like side effects of haloperidol have been speculated to involve several mechanisms. More recently, it has been speculated that the metabolic transformation to MPP+-like species may contribute to the Parkinsonism-like side effects. Because BCPP+ and its reduced analogue have been shown to possess the potential to destroy dopamine receptors in the nigrostriatum, we have designed new analogues of haloperidol lacking the structural features necessary to form neurotoxic quaternary species but retaining their dopamine-binding capacity. The most potent agent at the D2 receptor, the homopiperidine analogue 11, was found to be equipotent to haloperidol. It was also of interest to identify analogues with DA binding profiles similar to that of clozapine at the dopamine receptor subtypes. Evaluation of the proposed agents shows that the ratio of D2 to D4 (2) binding of clozapine was mimicked by 7 [Ki(D2) = 33, Ki(D3) = 200, Ki(D4) = 11 nM; Ki(D2)/Ki(D4) = 3] and 9 [Ki(D2) = 44, Ki(D3) = 170, Ki(D4) = 24 nM; Ki(D2)/Ki(D4) = 2]. A preliminary in-vivo testing of compound 7 shows that its behavioral profile is similar to that of clozapine. This profile suggests that there is a need for further evaluation of these two synthetic agents and their enantiomers for efficacy and lack of catalepsy in animal models.